Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 23, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Dec. 23, 2024 -- For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal of Gastroenterology.

Gursimran S. Kochhar, M.D., from the Allegheny Health Network in Pittsburgh, and colleagues conducted a retrospective cohort study to compare the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis. Data were included for 526 patients in the upadacitinib cohort and 1,149 in the tofacitinib cohort.

The researchers observed no significant difference in the risk for the composite outcome of hospitalization requiring intravenous steroids and/or colectomy within six months in a propensity score-matched analysis. However, the risk for the composite outcome was significantly lower in the upadacitinib cohort versus the tofacitinib cohort within 12 months. The risk for intravenous steroid use did not differ significantly, but risk for colectomy was lower. In a sensitivity analysis, the risk for the composite outcome was significantly lower, including a lower risk for intravenous steroid use and colectomy, in the upadacitinib cohort versus tofacitinib cohort within 12 months.

"Our study utilizing real-world data showed that over a 12-month period following initiation of a Janus kinase inhibitor, upadacitinib use compared with tofacitinib is associated with improved disease-specific outcomes in patients with ulcerative colitis," the authors write.

Several authors disclosed ties to pharmaceutical companies, including AbbVie, which manufactures upadacitinib.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-24 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords